APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant DNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant DNA Drug Market Outlook and Growth Opportunities 2026

23 December 2025208 pages

Choose your research edition.

Industry ResearchRecombinant DNA Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant DNA Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Recombinant DNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant DNA Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant DNA Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Recombinant DNA Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant DNA Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant DNA Drug market include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Recombinant DNA Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant DNA Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant DNA Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Recombinant DNA Drug market.

Recombinant DNA Drug Segment by Company

GenSci

Takeda

CSPC

3SBIO

Sandoz

Sanofi

Johnson & Johnson

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol-Myers Squibb

Amgen

AbbVie

Swedish Orphan Biovitrum

Organon Pharma

Recombinant DNA Drug Segment by Type

Fusion Protein

Recombinant Interleukin

Recombinant Interferon

Recombinant Hormone

Recombinant Coagulation Factor

Recombinant Growth Factor

Other

Recombinant DNA Drug Segment by Application

Infectious Diseases

Metabolic Disorders

Cancers

Autoimmune Diseases

Recombinant DNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant DNA Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Recombinant DNA Drug key companies, revenue, market share, and recent developments.

3. To split the Recombinant DNA Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Recombinant DNA Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant DNA Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant DNA Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant DNA Drug industry.

Chapter 3: Detailed analysis of Recombinant DNA Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Recombinant DNA Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Recombinant DNA Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant DNA Drug Industry Trends Table 2. Recombinant DNA Drug Industry Drivers Table 3. Recombinant DNA Drug Industry Opportunities and Challenges Table 4. Recombinant DNA Drug Industry Restraints Table 5. Global Recombinant DNA Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant DNA Drug Revenue Share by Company (2021-2026) Table 7. Global Recombinant DNA Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Recombinant DNA Drug Key Company Manufacturing Base & Headquarters Table 9. Global Recombinant DNA Drug Company, Product Type & Application Table 10. Global Recombinant DNA Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Recombinant DNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fusion Protein Table 15. Significant Companies of Recombinant Interleukin Table 16. Significant Companies of Recombinant Interferon Table 17. Significant Companies of Recombinant Hormone Table 18. Significant Companies of Recombinant Coagulation Factor Table 19. Significant Companies of Recombinant Growth Factor Table 20. Significant Companies of Other Table 21. Global Recombinant DNA Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Recombinant DNA Drug Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Recombinant DNA Drug Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Recombinant DNA Drug Sales Value Share by Type (2021-2026) Table 25. Global Recombinant DNA Drug Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Infectious Diseases Table 27. Significant Companies of Metabolic Disorders Table 28. Significant Companies of Cancers Table 29. Significant Companies of Autoimmune Diseases Table 30. Global Recombinant DNA Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Recombinant DNA Drug Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Recombinant DNA Drug Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Recombinant DNA Drug Sales Value Share by Application (2021-2026) Table 34. Global Recombinant DNA Drug Sales Value Share by Application (2027-2032) Table 35. Global Recombinant DNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Recombinant DNA Drug Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Recombinant DNA Drug Sales Value Share by Region (2021-2026) Table 38. Global Recombinant DNA Drug Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Recombinant DNA Drug Sales Value Share by Region (2027-2032) Table 40. Global Recombinant DNA Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Recombinant DNA Drug Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Recombinant DNA Drug Sales Value Market Share by Country (2021-2026) Table 43. Global Recombinant DNA Drug Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Recombinant DNA Drug Sales Value Market Share by Country (2027-2032) Table 45. GenSci Company Information Table 46. GenSci Business Overview Table 47. GenSci Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GenSci Recombinant DNA Drug Product Portfolio Table 49. GenSci Recent Development Table 50. Takeda Company Information Table 51. Takeda Business Overview Table 52. Takeda Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Takeda Recombinant DNA Drug Product Portfolio Table 54. Takeda Recent Development Table 55. CSPC Company Information Table 56. CSPC Business Overview Table 57. CSPC Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. CSPC Recombinant DNA Drug Product Portfolio Table 59. CSPC Recent Development Table 60. 3SBIO Company Information Table 61. 3SBIO Business Overview Table 62. 3SBIO Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. 3SBIO Recombinant DNA Drug Product Portfolio Table 64. 3SBIO Recent Development Table 65. Sandoz Company Information Table 66. Sandoz Business Overview Table 67. Sandoz Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sandoz Recombinant DNA Drug Product Portfolio Table 69. Sandoz Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Recombinant DNA Drug Product Portfolio Table 74. Sanofi Recent Development Table 75. Johnson & Johnson Company Information Table 76. Johnson & Johnson Business Overview Table 77. Johnson & Johnson Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Johnson & Johnson Recombinant DNA Drug Product Portfolio Table 79. Johnson & Johnson Recent Development Table 80. Novo Nordisk Company Information Table 81. Novo Nordisk Business Overview Table 82. Novo Nordisk Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novo Nordisk Recombinant DNA Drug Product Portfolio Table 84. Novo Nordisk Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Merck Recombinant DNA Drug Product Portfolio Table 89. Merck Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Recombinant DNA Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Roche Recombinant DNA Drug Product Portfolio Table 94. Roche Recent Development Table 95. Eli Lilly Company Information Table 96. Eli Lilly Business Overview Table 97. Eli Lilly Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Eli Lilly Recombinant DNA Drug Product Portfolio Table 99. Eli Lilly Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Pfizer Recombinant DNA Drug Product Portfolio Table 104. Pfizer Recent Development Table 105. GlaxoSmithKline Company Information Table 106. GlaxoSmithKline Business Overview Table 107. GlaxoSmithKline Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. GlaxoSmithKline Recombinant DNA Drug Product Portfolio Table 109. GlaxoSmithKline Recent Development Table 110. Biogen Company Information Table 111. Biogen Business Overview Table 112. Biogen Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Biogen Recombinant DNA Drug Product Portfolio Table 114. Biogen Recent Development Table 115. Bayer Company Information Table 116. Bayer Business Overview Table 117. Bayer Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Bayer Recombinant DNA Drug Product Portfolio Table 119. Bayer Recent Development Table 120. Bristol-Myers Squibb Company Information Table 121. Bristol-Myers Squibb Business Overview Table 122. Bristol-Myers Squibb Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio Table 124. Bristol-Myers Squibb Recent Development Table 125. Amgen Company Information Table 126. Amgen Business Overview Table 127. Amgen Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Amgen Recombinant DNA Drug Product Portfolio Table 129. Amgen Recent Development Table 130. AbbVie Company Information Table 131. AbbVie Business Overview Table 132. AbbVie Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. AbbVie Recombinant DNA Drug Product Portfolio Table 134. AbbVie Recent Development Table 135. Swedish Orphan Biovitrum Company Information Table 136. Swedish Orphan Biovitrum Business Overview Table 137. Swedish Orphan Biovitrum Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio Table 139. Swedish Orphan Biovitrum Recent Development Table 140. Organon Pharma Company Information Table 141. Organon Pharma Business Overview Table 142. Organon Pharma Recombinant DNA Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Organon Pharma Recombinant DNA Drug Product Portfolio Table 144. Organon Pharma Recent Development Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Recombinant DNA Drug Product Image Figure 2. Global Recombinant DNA Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant DNA Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fusion Protein Image Figure 8. Recombinant Interleukin Image Figure 9. Recombinant Interferon Image Figure 10. Recombinant Hormone Image Figure 11. Recombinant Coagulation Factor Image Figure 12. Recombinant Growth Factor Image Figure 13. Other Image Figure 14. Global Recombinant DNA Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant DNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant DNA Drug Sales Value Share by Type (2021-2032) Figure 17. Infectious Diseases Image Figure 18. Metabolic Disorders Image Figure 19. Cancers Image Figure 20. Autoimmune Diseases Image Figure 21. Global Recombinant DNA Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Recombinant DNA Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant DNA Drug Sales Value Share by Application (2021-2032) Figure 24. Global Recombinant DNA Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Recombinant DNA Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Recombinant DNA Drug Sales Value (2021-2032) & (US$ Million) Figure 27. North America Recombinant DNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Recombinant DNA Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Recombinant DNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Recombinant DNA Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Recombinant DNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Recombinant DNA Drug Sales Value (2021-2032) & (US$ Million) Figure 33. South America Recombinant DNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Recombinant DNA Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Recombinant DNA Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Recombinant DNA Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Protein
  • Recombinant Interleukin
  • Recombinant Interferon
  • Recombinant Hormone
  • Recombinant Coagulation Factor
  • Recombinant Growth Factor
  • Other
Applications
  • Infectious Diseases
  • Metabolic Disorders
  • Cancers
  • Autoimmune Diseases
Companies covered
  • GenSci
  • Takeda
  • CSPC
  • 3SBIO
  • Sandoz
  • Sanofi
  • Johnson & Johnson
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • Swedish Orphan Biovitrum
  • Organon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant DNA Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant DNA Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Recombinant DNA Drug Market Dynamics
  1. 2.1 Recombinant DNA Drug Industry Trends
  2. 2.2 Recombinant DNA Drug Industry Drivers
  3. 2.3 Recombinant DNA Drug Industry Opportunities and Challenges
  4. 2.4 Recombinant DNA Drug Industry Restraints
3 Recombinant DNA Drug Market by Company
  1. 3.1 Global Recombinant DNA Drug Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant DNA Drug Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant DNA Drug Company Ranking (2024-2026)
  4. 3.4 Global Recombinant DNA Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Recombinant DNA Drug Company Product Type and Application
  6. 3.6 Global Recombinant DNA Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Recombinant DNA Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Recombinant DNA Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Recombinant DNA Drug Market by Type
  1. 4.1 Recombinant DNA Drug Type Introduction
  2. 4.1.1 Fusion Protein
  3. 4.1.2 Recombinant Interleukin
  4. 4.1.3 Recombinant Interferon
  5. 4.1.4 Recombinant Hormone
  6. 4.1.5 Recombinant Coagulation Factor
  7. 4.1.6 Recombinant Growth Factor
  8. 4.1.7 Other
  9. 4.2 Global Recombinant DNA Drug Sales Value by Type
  10. 4.2.1 Global Recombinant DNA Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Recombinant DNA Drug Sales Value by Type (2021-2032)
  12. 4.2.3 Global Recombinant DNA Drug Sales Value Share by Type (2021-2032)
5 Recombinant DNA Drug Market by Application
  1. 5.1 Recombinant DNA Drug Application Introduction
  2. 5.1.1 Infectious Diseases
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Cancers
  5. 5.1.4 Autoimmune Diseases
  6. 5.2 Global Recombinant DNA Drug Sales Value by Application
  7. 5.2.1 Global Recombinant DNA Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant DNA Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Recombinant DNA Drug Sales Value Share by Application (2021-2032)
6 Recombinant DNA Drug Regional Value Analysis
  1. 6.1 Global Recombinant DNA Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant DNA Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Recombinant DNA Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Recombinant DNA Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant DNA Drug Sales Value (2021-2032)
  7. 6.3.2 North America Recombinant DNA Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Recombinant DNA Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Recombinant DNA Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Recombinant DNA Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Recombinant DNA Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Recombinant DNA Drug Sales Value (2021-2032)
  16. 6.6.2 South America Recombinant DNA Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Recombinant DNA Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Recombinant DNA Drug Sales Value Share by Country, 2025 VS 2032
7 Recombinant DNA Drug Country-level Value Analysis
  1. 7.1 Global Recombinant DNA Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant DNA Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Recombinant DNA Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Recombinant DNA Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Recombinant DNA Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Recombinant DNA Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Recombinant DNA Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GenSci
  2. 8.1.1 GenSci Company Information
  3. 8.1.2 GenSci Business Overview
  4. 8.1.3 GenSci Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GenSci Recombinant DNA Drug Product Portfolio
  6. 8.1.5 GenSci Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Recombinant DNA Drug Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 CSPC
  14. 8.3.1 CSPC Company Information
  15. 8.3.2 CSPC Business Overview
  16. 8.3.3 CSPC Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Recombinant DNA Drug Product Portfolio
  18. 8.3.5 CSPC Recent Developments
  19. 8.4 3SBIO
  20. 8.4.1 3SBIO Company Information
  21. 8.4.2 3SBIO Business Overview
  22. 8.4.3 3SBIO Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 3SBIO Recombinant DNA Drug Product Portfolio
  24. 8.4.5 3SBIO Recent Developments
  25. 8.5 Sandoz
  26. 8.5.1 Sandoz Company Information
  27. 8.5.2 Sandoz Business Overview
  28. 8.5.3 Sandoz Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sandoz Recombinant DNA Drug Product Portfolio
  30. 8.5.5 Sandoz Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Recombinant DNA Drug Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Recombinant DNA Drug Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Recombinant DNA Drug Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck Recombinant DNA Drug Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Roche Recombinant DNA Drug Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Recombinant DNA Drug Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Recombinant DNA Drug Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 GlaxoSmithKline
  74. 8.13.1 GlaxoSmithKline Company Information
  75. 8.13.2 GlaxoSmithKline Business Overview
  76. 8.13.3 GlaxoSmithKline Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline Recombinant DNA Drug Product Portfolio
  78. 8.13.5 GlaxoSmithKline Recent Developments
  79. 8.14 Biogen
  80. 8.14.1 Biogen Company Information
  81. 8.14.2 Biogen Business Overview
  82. 8.14.3 Biogen Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biogen Recombinant DNA Drug Product Portfolio
  84. 8.14.5 Biogen Recent Developments
  85. 8.15 Bayer
  86. 8.15.1 Bayer Company Information
  87. 8.15.2 Bayer Business Overview
  88. 8.15.3 Bayer Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bayer Recombinant DNA Drug Product Portfolio
  90. 8.15.5 Bayer Recent Developments
  91. 8.16 Bristol-Myers Squibb
  92. 8.16.1 Bristol-Myers Squibb Company Information
  93. 8.16.2 Bristol-Myers Squibb Business Overview
  94. 8.16.3 Bristol-Myers Squibb Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Recent Developments
  97. 8.17 Amgen
  98. 8.17.1 Amgen Company Information
  99. 8.17.2 Amgen Business Overview
  100. 8.17.3 Amgen Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Amgen Recombinant DNA Drug Product Portfolio
  102. 8.17.5 Amgen Recent Developments
  103. 8.18 AbbVie
  104. 8.18.1 AbbVie Company Information
  105. 8.18.2 AbbVie Business Overview
  106. 8.18.3 AbbVie Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AbbVie Recombinant DNA Drug Product Portfolio
  108. 8.18.5 AbbVie Recent Developments
  109. 8.19 Swedish Orphan Biovitrum
  110. 8.19.1 Swedish Orphan Biovitrum Company Information
  111. 8.19.2 Swedish Orphan Biovitrum Business Overview
  112. 8.19.3 Swedish Orphan Biovitrum Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio
  114. 8.19.5 Swedish Orphan Biovitrum Recent Developments
  115. 8.20 Organon Pharma
  116. 8.20.1 Organon Pharma Company Information
  117. 8.20.2 Organon Pharma Business Overview
  118. 8.20.3 Organon Pharma Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Organon Pharma Recombinant DNA Drug Product Portfolio
  120. 8.20.5 Organon Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst